OTC Pnk
SHARE STRUCTURE:
Authorized Shares
250,000,000,000
SHARES OUTSTANDING:
7,894,037,082
issued and outstanding as of November 19, 2014
an increase of 4,238,984,241
from the below
3,655,052,841
as of October 9, 2014
AUTHORIZED SHARES:
250,000,000,000
Common Stock from Ten Billion (10,000,000,000) shares of Common Stock to Two Hundred Fifty Billion (250,000,000,000) shares of Common Stock and (b) the Company’s preferred stock, par value $0.01 per share, from One Million (1,000,000) shares of preferred stock to Twenty-Five Million (25,000,000) shares of preferred stock
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10401892
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10244545
an increase of 1,299,077,468 between the above & below link
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10094756
1) Holders of some of our promissory notes which are now in default could, if they were to successfully enforce those notes in a law suit, levy on our assets and have them sold to satisfy our obligations on the notes.
2) Part of our debt held by promissory note holders has been assumed by Redwood Management, LLC. However, our bridge notes and our convertible promissory notes held by some of our promissory note holders are in default, and we are not in a position to repay them. We intend to use the proceeds of a future offering to pay off such notes. Holders of those notes could if they choose to sue on those notes, and if they were successful in their lawsuits they could levy on our assets and have those assets sold to satisfy the amounts we owe them.
3) As of May 9, 2014, we had 228 holders of record of our common stock and 2,230,314,377 shares of common stock issued and
outstanding.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9979496
I will gladly let the investing public decide as
during this time Victor & Anna sold $1.5M worth of notes/shares this was also happening
Quote:
TOTAL STOCKHOLDERS' DEFICIT (21,167,614) March 31, 2014 (9,849,067) December 31, 2013
an increase of 11,318,547 in just the 1st qtr
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
WHEN...just in the first qtr...that's WHEN Quote:
NET LOSS $ (13,004,773) $ (1,058,459)
an increase of $11,946,314
WHEN...just in the first qtr...that's WHEN
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
a share increase of 124,763,996 in 40 days Quote:
Number of shares of common stock issued and outstanding as of June 18, 2014 is 2,355,075,373.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
a share increase of 124,763,996 in 40 days
WHEN...just in 40 days...that's WHEN Quote:
Accumulated deficit (61,908,223) March 31, 2014 (48,903,450) December 31, 2013
an increase of $13,004,774 in just the 1st qtr
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
WHEN...just in the 1st qtr...that's...WHEN
a share increase of 124,763,996 in 40 days Quote:
Number of shares of common stock issued and outstanding as of June 18, 2014 is 2,355,075,373.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697
a share increase of 124,763,996 in 40 days Quote:
The number of outstanding shares of the Registrant’s Common Stock, $0.0001 par value, at May 9, 2014 was 2,230,314,377.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9979496
SVFC has NO CASH other than the Toxic Convertible Debentures they have been agreeing to but @ the terms Vic just got it would be even worse FACT & here are some terms
FACTS & TERMS
So we now know how the Ironridge note has been resolved & how Oing ruled on the IR Facility Fee issue
As of March 31st Dominion will get to convert $746,092.00 plus $1,088.00 in interest (@7.5%APR). That totals $747,180.00 at that time. The conversion is at 48.5% of the average three lowest trades of the 20 days prior to conversion. Quote:
Dominion Capital Debenture
On March 24, 2014, Ironridge Global sold the TCA Note to Dominion Capital under the security settlement agreement executed between the Company and Dominion Capital, and the Company issued a convertible debenture to Dominion Capital in the amount of $746,092 (the “Dominion Debenture”). The $746,092 principal balance included the original TCA Note of $500,000, accrued interest and pre-payment penalties of $246,092.
The Dominion Capital Debenture matures on March 24, 2015 and accrues interest at an annual rate equal to 7.5%. At any time, and at its sole option, Dominion Capital can to convert a portion or all amounts of principal and interest due and outstanding under the Dominion Debenture into shares of common stock at a price equal to 48.5% of the average of the three lowest prices per share of reported trades (not on the same day) of the common stock on the OTC Markets or on the exchange which the common stock is then listed as quoted by Bloomberg, LP during the 20 trading days preceding the conversion date.
As of March 31, 2014, the Dominion Debenture had a principal balance of $746,092, and accrued interest of $1,088.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10056697 Quote:
Part of our debt held by promissory note holders has been assumed by Redwood Management, LLC.
was only Victor & Anna were cashing in over $1.5M while also causing 31,720,856 shares to enter the market FACT the above was installed & can only be removed or edited by BigBadWolf & NO data/info may be placed above it as per admin Ms. Linda's private message to ALL MOD's
Publication in The American Journal ofMedicine showing regenerative results of cardiac function with SVFC's patented technology
Zain Khalpey, MD, PhD, Rajesh Janardhanan, MD, John Konhilas, PhD, Courtney Hemphill, BS.
First in Man: Adipose-derived Stromal VascularFraction Cells May Promote Restorative Cardiac Function, Amer J Med. 2014; 127,5: e11-e12
Article Outline
1. Case Summary
2. Discussion
3. Conclusions
To the Editor:
Despite advances in clinical intervention, heart disease remains a causation of mortality in the world. Research demonstrates that the adipose-derived stromal vascular fraction of cells contains multi-potent cells that exhibit mesodermal and ectodermal capacity and contain CD44+, CD90+, CD73+, CD105+, CD34+, and CD31+ cells, which act in tissue regeneration and vascular stabilization.1 We discuss a patient who underwent such cell administration as rescue therapy for failing cardiac function, despite conventional
Case Summary
The patient is a 73-year-old white man with a history of
hyperlipidemia who presented with recurrent angina pectoris, for which he had undergone multiple angioplasties and 9 coronary stents (right posterior descending and distal right coronary beyond a saphenous vein graft to right coronary artery). He had further percutaneous coronary intervention to the distal right coronary artery and proximal posterior descending branch. His prior coronary bypass artery graft of 3 vessels had been redone. Robotic-assisted transmyocardial revascularization for angina was performed in the patient 2 months before cell delivery. He had significant left ventricular systolic
dysfunction (ejection fraction, 20%) with a thinned, akinetic inferolateral segment. To evaluate left ventricular function, transesophageal echocardiography was performed in the patient.
As a last resort intervention for the patient's dysfunctional heart, 100 million adipose-derived stromal vascular fraction cells were delivered via localized intramyocardial injection (left apex), and 200 million adipose-derived stromal vascular fraction cells were delivered systemically via intravenous injection. The intracoronary delivery of freshly isolated autologous cells consisted of a complex cell composition. This uncultured population taken from lipoaspirate, which had an approximately 86% viability, consisted of CD34+ cells.
Within 7 days of the procedure, transesophageal echocardiography was performed to evaluate recovery of the patient's left ventricular function.
His ejection fraction improved to 35% with recovery in the contractility of the previously akinetic inferolateral segment. This confirmed the effectiveness of cell delivery in improving regional and global left ventricular systolic function.
Discussion
Spontaneous recovery of the damaged myocardium occurred. The effective delivery of the stromal vascular fraction cell population, which contained stem cells, may have improved regional and global left ventricular systolic function, aiding recovery. Adipose-derived stromal vascular fraction cells may have cardiomyogenic potential. Cellular composition of cells administered included endothelial progenitor cells, vascular smooth muscle cells, mesenchymal stem cells, fibroblasts, growth factors, and pericytes. This complex population has shown efficacy in repairing damaged tissue to partial restoration of functional normalcy.2
Angiogenesis may contribute to restoration of cardiac function through preservation of remaining viable and hibernating cardiomyocytes. This salvaging effect might be maintenance of border zone cells through stem cell–mediated anti-apoptotic and neoangiogenic effects, which are causative of stem cell–produced paracrine factors.1 This cell population has a high expression in DKK-1 and ID proteins, which are associated with regulation of stem cell proliferation and differentiation.2
Conclusions
We postulate that the intramyocardial
administration of multi-potent adipose-derived stromal vascular fraction cellsand their diverse composition guided engraftment in the damaged area,
facilitated the cardiomyocyte regenerative properties, and helped improve cardiac function.
Because subcutaneous adipose tissue is readily available in most patients, adipose-derived stromal vascular fraction cells present a feasible clinical intervention for cardiac dysfunction. The population complexity, which includes stromal vascular fraction and growth factors, likely promotes repair by recruiting cardiomyocytes. The autologous nature and multi-potency of these cells may contribute to them being ideal for cardiac function restoration.
Acknowledges
The authors thank Dr Steven Victor and Stephanie Squicciarini of IntelliCell Biosciences Inc (New York, NY) for supplying stromal vascular fraction, Dr Craig Hurst for providing lipoaspirate, and the patient and family.
References
Alt, E., Pinkernell, K., Scharalau, M. et al. Effect of freshly isolated autologous tissue resident stromal cells on cardiac function and perfusion following acute myocardial infarction. Int J Cardiol. 2009; 144: 26–35
View in Article | Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)
Lin, K., Matsubara, Masuda, Y. et al. Characterization of adipose tissue-derived cells isolated with Celution™ system. Cytotherapy. 2008; 10: 417–426
View in Article | Abstract | Full Text | Full Text PDF | PubMed | Scopus (64)
Funding: Provided by the University of Arizona College of Medicine, Department of Surgery, Division of Cardiothoracic
Surgery.
Conflict of Interest: None.
Authorship: All authors had access to the data and played a role in writing this manuscript.
http://www.amjmed.com/article/S0002-9343(14)00079-5/fulltext http://ih.advfn.com/p.php?pid=nmona&article=62010474 http://opa.ahsc.arizona.edu/newsroom/news/2013/heart-surgeon-zain-khalpey-appointed-lead-heart-transplant-program-mechanical-cir http://surgery.arizona.edu/faculty-profile/zain-khalpey-md-phd-mrcs http://marketwatch.com/story/intellicell-biosciences-announces-that-dr-zain-khalpey-has-joined-its-advisory-board-2013-06-17
START HERE. SVFC DD COMPILATION. ***Updated: 1/30/2014*** Table of Contents: 1) The Industry
2) The Company
3) The People
4) The Science
5) The Patents
6) The Due Diligence
1) The Industry Regenerative Medicine (RM) is currently a $15 billion market and is expanding rapidly.
In fact, many are calling this LARGELY UNTAPPED market "The Internet of Healthcare," and it is projected to reach $300 billion by year 2020 as patient advocacy groups demanding shift to RM proliferate worldwide (source: US Department of Health and Human Services). 1.2 million patients have been treated to date with RM products and therapies. Currently, 300 private and 50 public companies exist with $4.7 billion in total market capacity. $1.5 billion in worldwide research funding projected to $14 billion in 10 years.
2) The Company The Company's Website Synopsis: Intellicell is an emerging leader in regenerative medicine using highly potent stromal vascular fraction cells derived from vasculature of fat tissue via uniquely efficacious technology that is
patented in the United States with multiple patents pending internationally. The company is intentioned to enter the
large and rapidly growing market of medical conditions where cellular therapies are far more effective than traditional techniques alone.
MOST RECENT SHARE STRUCTURE: SHARES OUTSTANDING:1,369,825,849 as of January 28, 2014 (latest filing)
AUTHORIZED SHARES:1,500,000,000
3) The People The CEO Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for
IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. He has been a
sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been
featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology.
Board of Directors Mr. Michael Hershman IntelliCell BioSciences Appoints Mr. Michael Hershman as Chairman of the Board of Directors Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security.
President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business. More on Mr. Hershman can be found on the website of Fairfax Group by following this link. Here is a video in which Michael Hershman is awarded Columbia Business School’s 2013 Botwinick Prize in Business Ethics. I suppose having a
renowned business ethics expert and a
successful businessman with multiple governmental connections as your BOD Chairman is not a bad thing ;)
Mr. Myron Holubiak Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc.
From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.
Mr. Leonard L. Mazur Mr. Leonard L. Mazur
Co-founded Triax Pharmaceuticals, LLC and serves as its Chief Operating Officer. Mr. Mazur also
Co-Founded Akrimax Pharmaceuticals in 2007. Mr. Mazur began his pharmaceutical career with Cooper Laboratories in 1971, where he served as a Product Manager for ophthalmology, dermatology and other products. He was
responsible for creating and growing the business that was sold to Pierre Fabre, a French dermatology company, in 2002. In 1995, he
founded Genesis Pharmaceutical, Inc., and served as its Chairman, Chief Executive Officer from 1995 to 2005 and President.
Mr. Sam Khashman IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman to Board of Directors During the past 20 years, Mr. Khashman has
successfully directed the creation and launch of 14 products and 3 companies in the healthcare, financial, and manufacturing sector. He currently serves as the President and Chief Executive Officer of Technology Partners, Inc. DBA IMAGINE Software. Mr. Khashman
founded the company and created the IMAGINE practice management system that is currently used in 48 States by more than 10,000 physicians. In addition to his involvement in numerous civic and charitable organizations, Mr. Khashman
serves on the board of the National Chamber Foundation, the public policy think tank of the U.S. Chamber of Commerce in Washington D.C. Medical Advisory Board Dr. James Andrews IntelliCell BioSciences Inc. Announces James R. Andrews, M.D. Has Joined Its Medical Advisory Board Doctor James Andrews is
one of the founding members of Andrews Sports Medicine and Orthopaedic Center in Birmingham, Alabama. He is also a
founder of the American Sports Medicine Institute (ASMI) a non-profit institute dedicated to injury prevention, education and research in orthopaedics and sports medicine. This foundation is recognized as one of the world’s leaders in this field. Doctor Andrews is internationally known and recognized for his skills as an orthopaedic surgeon as well as his scientific and clinic research contributions in knee, shoulder and elbow injury prevention and treatment. In addition,
he has made major presentations on every continent, and has authored numerous scientific articles and books. Everything you ever wanted to know about Dr. Andrews and how prominent he is in the athletic community can be found following this link. Credit: Sibware A list of athletic celebrities treated by Dr. Andrews as of 5 years ago can be found following this link. Could some of his NEW celebrity patients have been treated with the help of Intellicell’s technology, but not yet publicized? Dr. Joshua Hackel. Another member of Andrews Institute on Intellicell’s board of medical advisors is Dr. Joshua Hackel.
His profile information can be found here. Dr. Sydney Coleman You can read more about Dr. Coleman's extensive stem cell projects funded by the Department of Defense through the Office of the Assistant Secretary of Defense for Health Affairs in this post by lee13. Note that these fantastic people are just part of the group currently working to move Intellicell’s technology forward. Complete corporate profile for the company can be found following this link. Just Google some of the names not mentioned in this post to see that Intellicell is associated with crème de la crème of medical and scientific communities. 4) The Science According to this PR, an antibody flow cytometry study of IntelliCell's technology was performed by Millipore, a division of Merck (NYSE: MRK) and found that: "IntelliCell's proprietary technology yield an average of 10 times (10X) the number of SVF cells containing adult adipose stem cells from less fat (only 2 oz) than that which the Company believes is used by any of its present competition utilizing enzymes in their process. The study also showed that IntelliCells™ contain all of the viable cells that are manufactured by competing technologies that use enzymatic digestion." Click on this link to see the original figures from the Millipore studies of Intellicells. Credit: cazual The following image presents cell culturing report using Intellicell’s technology: 
Moreover, it is because no enzymes are necessary in Intellicell’s process that they are the only public commercial stem cell company in the United States to meet FDA Rule 361 exemption. Under the FDA’s Rule 361, IntelliCells is currently authorized to commercially sell its SVF stem cells in the U.S. The PR announcing the most recent FDA inspection of the company’s flagship lab can be found here. The copy of the FDA report can be obtained by following this link. Note that most of the observations cited in the report are minor and can be corrected easily. When the FDA spends four days in ANY lab, they WILL find something – it’s just the way the game goes. Additionaly, the company previously announced that “it has received the results of its independent laboratory audit by Biologic Consultant Group and the audit showed that the new lab at 460 Park Avenue, New York, NY was cGTP compliant.” Futhermore, as announced here, Intellicell “has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product.” Intellicell Biosciences wins key listing from the FDA Finally, according to this news release, Intellicell “has been granted a Research Tissue Banking License by the New York State Department of Health.” Which will now allow the company to engage in “the development of autologous and allogenic stromal vascular fraction tissue for researchers around the world.” A great summary of Intellicell’s technology as compared to current competitors can be found on page 19 of the company’s most recent investor presentation. The visual comparison is presented below: 
A list of Intellicell’s current human clinical trials, as officially reported by the company in the latest investor presentation can be found in this post by lee13. Here is an additional link to a prospective pilot study using Intellicell’s technology on the successful clinical application of SVFC on the gingival recession defects. And an additional link to a planned study using Intellicell’s technology for Diabetic Foot Ulcers. Finally, following is a collection links to official progress reports by the company in regards to successful use of technology for some of the most prominent conditions in today’s healthcare. IntelliCell Biosciences' Cellular Therapy Treatment Yields Positive Results in Multiple Sclerosis Patients IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis IntelliCell Biosciences Stem Cells Used to Successfully Treat Bell's Palsy and Type I Diabetes Patient Moreover, Dr. Babak Azizzadeh, one of the more prominent doctors in the nation, certainly a superstar in his field, acknowledges the Intellicell’s success. Babak Azizzadeh, MD, FACS, Director of the Facial Paralysis Institute, comments on the recent treatment of a Bell’s palsy patient with stromal vascular fraction cells. 5) The Patents IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology You can find the U.S. patent overview here. But not only is Intellicell’s technology fully patented in the United States, there are also multiple international patent applications that are pending. Links to European, Australian, Canadian, Thailand and Korean patents can be found in cazual’s post following this link. It is clear that these patents when granted will open up a whole world of unique revenue-generating possibilities, especially in the countries and jurisdictions where stem cell laws and regulations are much more progressive than in the United States. And the most important patent of them all, the European one, is one final step away from being granted! The news could come any day now! See the image below (courtesy of Sir Francelote) 
6) The Due Diligence In December 2013, Dr. Victor returned back from the business trip to a world-renowned hospital in Korea that is actively engaged in stem cell treatments of international celebrities. Related DD and picture confirmation of the trip can be found in this post. Another impressive picture from the CEO's Korean trip can be seen here. (Source: Dr. Victor's Twitter Account) More amazing pictures from the Korean trip can be found in this post by click5. Here is a list of medical staff from CHAUM Global Stem Cell Clinical Trials Center. Find the pictures of Intellicell's flagship clinic by following this link. Credit: Sir Francelote Stervc’s comparison and contrast between SVFC and their main competitor CYTX can be seen here. Stervc's post on SVFC & Bereskin & Parr LLP connection can be found by following this link. Some notes on why Intellicell's process without enzymes is superior to that of CYTX, can be read in this post and also here. You can read my thoughts on why Intellicell's debt is not all that bad by following this link. The company's business plan is discussed here. Forbes article discussing Intellicell's advantage. “A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.” Some calculation and comparison of cell yield from Intellicell and their competitors can be found in this post. As shown here some of the insiders do believe in this company enough to trust it with couple hundred thousand dollars out of their own pockets. Here is a link to a post by iHub member LJ Silver about a mystery investor who was willing to provide Intellicell with $500,000 of cold, hard cash. Sir Francelote provides some quick DD in regards to where Intellicell stands against its competitors in this post. lee13 shares some good thoughts on the likelihood of a buyout in this post. Even if the FDA fails to support stem cell industry in the US – multiple international patents (See “The Patents”) will open up countless business possibilities abroad, where regulations in regards to human use of stem cells is much more progressive. And let’s not forget that Intellicell can still explore and capitalize upon less regulated US markets in cosmetics and veterinarian care. In fact, the company has already investigated veterinary market as per this PR. Let’s not forget that the CEO is NOT getting paid until Intellicell is generating some significant revenues as explained by TheSkunk. If you ever wondered about the reasons why Intellicell used to trade at $4 but is now a penny stock, you can read some thoughts on this matter that are posted right here. You can read about Intellicell's relationship with ReGen Clinic by following this link. MUST-VISIT LINKS Most Recent Investor Presentation (February 2013) Most Recent (7.11.2013) Intellicell's CEO interview (Audio) Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process (July 8, 2013) The CEO’s Twitter Account Best of luck! i.t.m.d.
INTELLICELL BIOSCIENCES, INC.
About IntelliCell BioSciences, Inc.
IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.
IntelliCell was formed to take a leading role and harmonize the interests of all the stakeholder communities in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.
The VFC cells that are being processed by IntelliCell are known as autologous cells. That is the donor of cells and the recipient of the cells are the same person. IntelliCell is unique as it does not use any chemicals or biological agents such as collagenese in its proprietary and patent pending process. The Company has developed a novel ultrasound process to assist the laboratory in the preparation of the VFC cells. In a process similar to the acquisition of autologous stem cells from bone marrow aspirate, the IntelliCell VFC cells are being given to physicians working in the field of regenerative medicine.
LATEST SHAREHOLDER LETTER
NEW YORK, NY--(Marketwired - Dec 10, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, provides shareholder update.
Dear Valued Shareholders,
On behalf of myself, the Board of Directors and the entire IntelliCell team, I would like to let you know that we are pleased with the growth initiatives that we have accomplished since our initial shareholder letter.
Now is an important and exciting time for IntelliCell Biosciences. We have continued to improve our competitive position in the regenerative medicine field and I believe we have never been stronger or better positioned for future growth. The worldwide regenerative medicine market is being driven by previously unseen treatments and procedures that are improving the quality of life of patients around the world and we firmly believe that we will emerge as one of the leaders in this industry.
The Company has been executing on our strategic plan and business priorities this year. We have made advancements in our technology and have filed patents around the world for our proprietary regenerative medical solutions. I am encouraged by the expanding market presence of IntelliCell Biosciences and the escalating acceptance of the Company's products and solutions within the medical, scientific and investment community. Additionally, we continue to work hard at improving our balance sheet and financial position, in order to have the necessary resources to take advantage of our growth opportunities. Because of all these accomplishments, I believe we are better positioned than ever for growth.
We have focused primarily on three strategic initiatives, Growth, Leverage, and Financial Strength, in order to improve the overall standing of the company.
Growth: We will continue to grow and supply our cellular product to physicians to treat their patients with clinical needs. We intend to be a major provider of minimally manipulated stromal vascular fraction cells SVFCs for autologous use to physicians and achieve exciting clinical results that improve the quality of life for their patients.
Leverage: We are leveraging our scale and best practices to create a cost-effect business model that increases our competitive advantage over our industry peers. Our intent is to open 3 additional facilities in 3 states in the next 12 months. Once the model is perfected, we will roll out additional facilities at a more aggressive pace. As the regenerative medical market expands, we intend to be the most recognized name in the industry.
Financial Strength: We have a goal of improving our balance sheet and income statement in order to deliver strong shareholder returns. Currently we are enacting a plan to remove all debt from our balance sheet. Going forward, it is our intent to use equity capital for the advancement of our company. Believing that IntelliCell Biosciences stock is undervalued, I will be converting a portion of my debt into shares and will continue this practice going forward. These measures will enable us to continue implementing our business and open new Cellular Labs in hospitals and ambulatory surgical centers that will significantly increase our revenues.
We are committed to advance the regenerative medicine field. This will enable us to become more productive, reliable and cost effective than ever before. IntelliCell's physician partners have informed us that we are well-aligned with their strategic intentions, and their clinical and business priorities. These are the key priorities that will ensure IntelliCell's future success.
As many of you know, our technology is new and cutting edge and requires acceptance by the marketplace and the regulators. We will remain aggressive in our efforts to overcome industry obstacles so that our medical solutions can serve as the industry standard. The Company has successfully developed advanced medical technologies, most notably its patented process of isolating SVFCs from adipose (fat) tissue using a mechanical technique, exclusive to the industry of regenerative medicine, now being used by physicians to treat patients with previously unmet clinical needs.
Management firmly believes that regenerative medicine is the future of medicine and we intend to aggressively expand our market footprint in order to solidify our position as the leader in the field. We would like to express our gratitude to our loyal global customer base and we are grateful to our shareholders for their continued support and ownership in our company. As CEO and Founder of IntelliCell, my paramount responsibility is to enhance shareholder value. I take immense pride in the success of this company to date and remain committed to delivering the best products and services possible to increase market presence in the future.
We at IntelliCell Biosciences are confident that our vision and goals will be achieved.
Sincerely,
Dr. Steven Victor
Chief Executive Officer
IntelliCell Biosciences, Inc.
Link to the most recent FDA Inspection Form 483 issued on 06/06/2013 http://www.ipscell.com/wp-content/uploads/2013/08/Intellicell-483_2013.pdf
RELEVANT LINKS
DD COMPILATION (January 30, 2014)
http://www.intellicellbiosciences.com
https://twitter.com/stevenvictormd
DAILY CHART
News 
Market Data 
Discover 
